Vitamin D and bone - How does vitamin D regulate bone formation and resorption?

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 80, Issue 9, 2004, Pages 407-421

  Suda, Tatsuo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

1 ,25 dihydroxyvitamin D3; Bone formation and resorption; Osteoblasts; Osteoclasts; Receptor activator of NF B ligand (RANKL); Vitamin D

Indexed keywords

EID: 14644394925     PISSN: 03862208     EISSN: None     Source Type: Journal    
DOI: 10.2183/pjab.80.407     Document Type: Review

References (77)

1. Suda, T., Takahashi, N., and Martin, T. J. (1992) Modulation of osteoclast differentiation. Endocr. Rev. 13, 66-80.
2. DeLuca, H. F. (1988) The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J. 2, 224-236.
3. Ponchon, G., Kennan, A. L., and DeLuca, H. F. (1969) " Activation" of vitamin D by the liver. J. Clin. Invest. 48, 2032-2037.
4. 3-25-hydroxylase from rat liver mitochondria. Fed. Eur. Biol. Lett. 262, 135-138.
5. 3-25-hydroxylase from rat liver mitochondria. J. Biol. Chem. 255, 5244-5249.
6. 3. Biochemistry 7, 3317-3322.
7. Suda, T., DeLuca, H. F., Schnoes, H. K., and Blunt, J. W. (1969) Isolation and identification of 25-hydroxyergocalciferol. Biochemistry 8, 3515-3520.
8. Fraser, D. R., and Kodicek, E. (1970) Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228, 764-766.
9. Holick, M. F., Schnoes, H. K., DeLuca, H. F., Suda, T., and Cousins, R. J. (1971) Isolation and identification of 1,25-dihydroxycholecalciferol: A metabolite of vitamin D active in intestine. Biochemistry 10, 2799-2804.
10. Lawson, D. E. M., Fraser, D. R., Kodicek, E., Morris, H. R., and Williams, D. H. (1971) Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 230, 228-230.
11. 3-1α-hydroxylase cDNA. Proc. Natl. Acad. Sci. USA 94, 12920-12925.
12. 3-1α-hydroxylase and vitamin D synthesis. Science 277, 1827-1830.
13. St. Arnaud, R., Messerlian, S., Moir, J. M., Omdahl, J. L., and Glorieux, F. H. (1997). The 25-hydroxyvitamin D-1α-hydroxylase gene maps to the pseudovitamin D deficiency rickets (PDDR) disease locus. J. Bone Miner. Res. 12, 1552-1559.
14. Fu, G. K., Lin, D., Zhang, M. Y. H., Bikle, D. D., Shackleton, C. H. I., Miller, W. L., and Portale, A. A. (1997) Cloning of human 25-hydroxyvitamin D-1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Molecular Endocrinology 11, 1961-1970.
15. 3 made in the kidney. Biochemistry 11, 4251-4255.
16. 3. J. Biol. Chem. 266, 8690-8695.
17. DeLuca, H. F., and Schnoes, H. K. (1976) Metabolism and action of vitamin D. Annu. Rev. Biochem. 45, 631-666.
18. 3 in rat kidney but not in intestine. J. Biol. Chem. 267, 13757-13762.
19. 3 metabolism. J. Biol. Chem. 253, 8474-8478.
20. 3. Proc. Natl. Acad. Sci. USA 76, 5485-5489.
21. Haussler, M. R. (1986) Vitamin D receptors: nature and function. Annu. Rev. Nutr. 6, 527-562.
22. 3- and butyrate-inducible responses. Proc. Natl. Acad. Sci. USA 90, 2984-2988.
23. 3-24-hydroxylase gene. J. Biol. Chem. 269, 10545-10550.
24. Yoshizawa, T., Handa, Y., Uematsu, Y., Takeda, S., Sekine, K., Yoshihara, Y., Kawakami, T., Arioka, K., Sato, H., Uchiyama, Y. et al. (1997) Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16, 391-396.
25. 3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J. Biol. Chem. 269, 23750-23756.
26. Tanaka, H., and Seino, Y. (2004) Direct action of 1,25-dihydroxyvitamin D on bone: VDR KO bone shows excessive bone formation in normal mineral conditions. J. Steroid Biochemistry & Molecular Biology 89-90, 343-345.
27. Carlsson, A. (1952) Tracer experiments on the effects of vitamin D on the skeletal metabolism of calcium and phosphorus. Acta Physiol. Scan. 26, 212-220.
28. Raisz, L. G., Trummel, C. L., Holick, M. F., and DeLuca, H. F. (1972) 1,25-dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science 175, 768-769.
29. 3. Proc Natl. Acad. Sci. USA 78, 4990-4994.
30. Tanaka, H., Abe, E., Miyaura, C., Kuribayashi, T., Konno, K., Nishii, Y., and Suda, T. (1982) 1α,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem. J. 204, 713-719.
31. 3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc. Natl. Acad. Sci. USA 80, 5583-5587.
32. Rodan, G. A., and Martin, T. J. (1981) Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif. Tissue Int. 33, 349-351.
33. Chambers, T. J. (1992) Regulation of osteoclast development and function. In Biology and Physiology of the Osteoclast (eds. Rifkin, B. R., and Gay, C. V.). CRC Press, Boca Raton, FL, pp. 105-128.
34. 3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. Endocrinology 123, 1504-1510.
35. Suda, T., Udagawa, N., Nakamura, I., Miyaura, C., and Takahashi, N. (1995) Modulation of osteoclast differentiation by local factors. Bone 17, 87S-91S.
36. btsA58 transgenic mouse. Proc. Natl. Acad. Sci. USA 90, 5578-5582.
37. Tanaka, S., Takahashi, N., Udagawa, N., Tamura, T., Akatsu, T., Stanley, E. R., Kurokawa, T., and Suda, T. (1993) Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91, 257-263.
38. Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., and Shultz, L. D. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442-444.
39. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T. et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.
40. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., and Higashio, K. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142.
41. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M. et al. (1988) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337.
42. Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa; N., Yasuda, H., Mochizuki, S. et al. (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem. Biophys. Res. Commun. 247, 610-615.
43. Udagawa, N., Takahashi, N., Akatsu, T., Sasaki, T., Yamaguchi, A., Kodama, H., Martin, T. J., and Suda, T. (1989) The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in co-cultures with mouse spleen cells. Endocrinology 125, 1805-1813.
44. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A. et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602.
45. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S. et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
46. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S. 3rd, Frankel, W. N. et al. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194.
47. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
48. Riggs, B. L., Baron, R., Boyle, W. J., Drezner, M., Manolagas, S., Martin, T. J., Stewart, A. F., Suda, T., Yasuda, H., Aubin, J., and Goltzman, D. (2000) Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research (ASBMR) President's Committee on Nomenclature. J. Bone Miner. Res. 15, 2293-2296.
49. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., and Martin, T. J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357.
50. Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., and Higashio, K. (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253, 395-400.
51. Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R. et al. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424.
52. Li, J., Sarosi, I., Van, X. Q., Morony, S., Capparelli, C., Tan, H. L., McCabe, S., Elliott, R., Scully, S., Van, G. et al. (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97, 1566-1571.
53. Quinn, J. M. W., Itoh, K., Udagawa, N., Hausler, K., Yasuda, H., Shima, N., Mizuno, A., Higashio, K., Takahashi, N., Suda, T. et al. (2001) Transforming growth factor β affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 161, 1787-1794.
54. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L. et al. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268.
55. Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H., and Mumm, S. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. New Engl. J. Med. 347, 175-184.
56. Burgess, T. L., Qian, Y., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R. et al. (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538.
57. Mizuno, A., Kanno, T., Hoshi, M., Shibata, O., Yano, K., Fujise, N., Kinosaki, M., Yamaguchi, K., Tsuda, E., Murakami, A. et al. (2002) Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J. Bone Miner. Metab. 20, 337-344.
58. Hughes, A. E., Ralston, S. H., Marken, J., Bell, C., MacPherson, H., Wallace, R. G. H., van Hul, W., Whyte, M. P., Nakatsuka, K., Hovy, L., and Anderson, D. M. (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genet. 24, 45-48.
59. Whyte, M. P., and Hughes, A. E. (2002) Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J. Bone Miner. Res. 17, 26-29.
60. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A. et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.
61. Kim, N., Odgren, P. R., Kim, D. K., Marks, S. C. Jr., and Choi, Y. (2000) Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc. Natl. Acad. Sci. USA 97, 10905-10910.
62. Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H. L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540-3545.
63. Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K., Nakamura, K., Katsuki, M., Yamamoto, T., and Inoue, J. (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4, 353-362.
64. Lomaga, M. A., Yeh, W. C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S. et al. (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024.
65. Soriano, P., Montgomery, C., Geske, R., and Bradley, A. (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702.
66. Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Möhle-Steinlein, U., Rüther, U., and Wagner, E. F. (1992) Bone and hematopoietic defects in mice lacking c-fos. Nature 360, 741-745.
67. Grigoriadis, A. E., Wang, Z. Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., and Wagner, E. F. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448.
68. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., and Siebenlist, U. (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496.
69. Iotsova, V., Caamaño, J., Loy, J., Yang, Y., Lewin, A., and Bravo, R. (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Med. 3, 1285-1289.
70. Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., and Dunstan, C. R. (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360.
71. Body, J. J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J. P., Harousseau, J. P., Lipton, A., Mariette, X., Williams, C. D. et al. (2003) A phase I study of AMGEN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma-related bone metastasis. Cancer 97, 887-892.
72. Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., and DePaoli, A. M. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059-1066.
73. Louie, S. G., Park, B., and Yoon, H. (2003) Biological response modifiers in the management of rheumatoid arthritis. Am. J. Health Syst. Pharm. 60, 346-355.
74. Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N. et al. (2000) Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191, 275-286.
75. Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., and Kudo, A. (2000) Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275, 4858-4864.
76. Lam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., and Teitelbaum, S. L. (2000) TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488.
77. Suda, T., Ueno, Y., Fujii, K., and Shinki, T. (2003) Vitamin D and bone. J. Cell. Biochem. 88, 259-266.